Globus Medical Inc. Class A Common Stock vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $201.08 (market cap $37.46B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 3.7× Globus Medical Inc. Class A Common Stock's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days on average.
| GMED | TTWO | |
|---|---|---|
Market Cap | $10.25B | $37.46B |
Volume | 1,108,124 | 5,201,670 |
Sector | Health | Technology |
52-Week High | $96.82 | $262.29 |
52-Week Low | $58.33 | $189.69 |
Typical Hold Time | 0 Days | 111 Days |
Enterprise Value | $9.76B | $38.57B |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Take-Two Interactive (TTWO) trades at $201.23, down 3.63% today amid mixed technical signals and volatile earnings performance. The stock shows strong analyst support with 79% buy ratings and a $292.30 consensus price target, representing 45% upside potential. Recent quarterly results have been inconsistent with two beats and one miss, while the company maintains anticipation for Grand Theft Auto VI's November 2026 launch. Fundamentals reveal significant losses with a -79.51% net margin in 2025, though revenue growth continues and cash position remains strong at $1.47 billion.
The investment case hinges on GTA VI's successful execution, with current valuation reflecting high expectations. While analyst optimism remains strong, investors face risks from execution missteps, competitive pressures, and the stock's premium valuation multiples. The substantial negative earnings and cash flow volatility require careful monitoring, though institutional ownership trends show continued confidence in the long-term gaming franchise strategy.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →